Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDENV-PIV and TDENV-F17 Heterologous Prime Boost Dengue Vaccine Study
NCT03110952Phase 1Withdrawn
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Jan 2016
- Primary completion
- Apr 2017
- Modality
- Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of TDENV-PIV and T-DEN vaccine in dengue fever, sponsored by U.S. Army Medical Research and Development Command. Planned start Jan 2016; status: withdrawn.
02
Drugs
TDENV-PIVT-DEN vaccine
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT03110952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110952.